Expansion Therapeutics
Mark Ledeboer is an accomplished drug discovery expert currently serving as Senior Vice President of Drug Discovery at Expansion Therapeutics since June 2021, where the focus is on small molecule medicines for RNA-mediated diseases. Prior experience includes roles at Goldfinch Bio as Vice President of Drug Discovery and Chemistry, and at Vertex Pharmaceuticals as a Research Fellow and Senior Staff Investigator, engaging in various small molecule therapeutic programs and kinase target discovery. Ledeboer began their academic career as a Graduate Research Assistant at Brown University, earning both a PhD in Synthetic Organic Synthesis and a Master's in Organic Chemistry, following an undergraduate degree in Chemistry from Lafayette College. Early research includes significant contributions as an NIH Postdoctoral Fellow at The Scripps Research Institute under Dale L. Boger, concentrating on the synthesis of potent natural products.
This person is not in any offices
Expansion Therapeutics
2 followers
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. Expansion has assembled the intellectual property, know-how, and proprietary enabling technologies and tools necessary to facilitate the creation of potent and specific small molecule binders of RNA. Through this unique platform, Expansion is building a portfolio of novel RNA-targeted drug candidates with activity across a broad number of disease indications. The company’s initial development focus is on therapies for patients with expansion repeat diseases who currently have limited and unsatisfactory treatment options. Expansion is based in San Diego, California and Jupiter, Florida.